MaaT Pharma Stock price

Equities

MAAT

FR0012634822

Biotechnology & Medical Research

Market Closed - Euronext Paris 12:35:18 2024-03-28 pm EDT 5-day change 1st Jan Change
8.8 EUR -5.38% Intraday chart for MaaT Pharma -2.87% +26.07%
Sales 2023 * 5M 5.39M Sales 2024 * 5M 5.39M Capitalization 102M 110M
Net income 2023 * -23M -24.81M Net income 2024 * -24M -25.89M EV / Sales 2023 * 17.9 x
Net cash position 2023 * 12.7M 13.7M Net Debt 2024 * 20.15M 21.74M EV / Sales 2024 * 24.5 x
P/E ratio 2023 *
-3.71 x
P/E ratio 2024 *
-3.51 x
Employees 51
Yield 2023 *
-
Yield 2024 *
-
Free-Float 55.62%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on MaaT Pharma

1 day-5.38%
1 week-2.87%
Current month+10.83%
1 month+3.53%
3 months+22.91%
6 months+61.76%
Current year+26.07%
More quotes
1 week
8.80
Extreme 8.8
9.56
1 month
7.64
Extreme 7.64
9.60
Current year
6.40
Extreme 6.4
9.60
1 year
4.50
Extreme 4.5
10.50
3 years
4.50
Extreme 4.5
14.40
5 years
4.50
Extreme 4.5
14.40
10 years
4.50
Extreme 4.5
14.40
More quotes
Managers TitleAgeSince
Founder - 13-12-31
Director of Finance/CFO - 15-12-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 54 13-12-31
Director/Board Member 61 20-07-15
Director/Board Member - -
More insiders
Date Price Change Volume
24-03-28 8.8 -5.38% 2,982
24-03-27 9.3 -0.21% 1,240
24-03-26 9.32 +0.87% 681
24-03-25 9.24 +1.54% 1,129
24-03-22 9.1 +3.88% 1,189

Real-time Euronext Paris, March 28, 2024 at 12:35 pm EDT

More quotes
MaaT Pharma is specialized in the research and development of microbiome biotherapies for use in the treatment of solid cancer tumors. The company has a portfolio of 2 products in clinical development, including 1 in Phase III (MaaT013 for the treatment of acute graft-versus-host disease) and 1 in Phase IIb (MaaT033 for the prevention of complications of allogeneic hematopoietic stem cell transplantation), and 1 product in preclinical development (MaaT03X for the improvement of the response to immune checkpoint inhibitors in various types of solid tumors).
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
8.8 EUR
Average target price
15.25 EUR
Spread / Average Target
+73.30%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock MaaT Pharma - Euronext Paris